key: cord-0826432-0tgo6kxb
authors: Sharma, Shilpa; Deep, Shashank
title: In-silico drug repurposing for targeting SARS-CoV-2 main protease (M(pro))
date: 2020-11-12
journal: Journal of biomolecular structure & dynamics
DOI: 10.1080/07391102.2020.1844058
sha: 61dd9f5feec7ee4e4c48113ec5c73c2d0f8e2361
doc_id: 826432
cord_uid: 0tgo6kxb

COVID-19, caused by novel coronavirus or SARS-CoV-2, is a viral disease which has infected millions worldwide. Considering the urgent need of the drug for fighting against this infectious disease, we have performed in-silico drug repurposing followed by molecular dynamics (MD) simulation and MM-GBSA calculation. The main protease (M(pro)) is one of the best-characterized drug targets among coronaviruses, therefore, this was screened for already known FDA approved drugs and some natural compounds. Comparison of docking and MD simulation results of complexes of drugs with that of inhibitor N3 (experimentally obtained) suggests EGCG, withaferin, dolutegravir, artesunate as potential inhibitors of the main protease (M(pro)). Further, in silico docking and MD simulation suggest that EGCG analogues ZINC21992196 and ZINC 169337541 may act as a better inhibitor. Communicated by Ramaswamy H. Sarma

A new coronavirus, named SARS-CoV-2, has started from Wuhan, China and spread over the world (Shereen et al., 2020; Wu et al., 2020; Zhou et al., 2020) . It is a severe acute respiratory syndrome-related coronavirus (Gorbalenya et al., 2020) . The coronavirus disease, COVID-19 has affected 213 countries and territories around the world, among them USA, Brazil, Russia, India, UK, Spain, Italy and Peru are the worsthit countries having over 4.89 million infections combined. As of June 14, 2020, around 7.89 million people have been infected, and 0.432 million have died (https://www.worldometers.info/coronavirus/). The number of corona cases is increasing exponentially and not a single vaccine or drug is available for the treatment. Initially, antimalarial drugs chloroquine and hydroxychloroquine (Principi & Esposito, 2020; Singh et al., 2020) was proposed as treatment, however, recent studies have not shown any advantages and is associated with some side effects which can be life-threatening. The development of a vaccine will still one year away and there is a strong need for repurposing an already known drug which can block the activity of virus.

Coronaviruses are a large family of RNA viruses that are encapsulated inside a membrane envelope. Envelop have proteins appearing like spikes sticking out from their surface (Walls et al., 2020) . Main protease (M pro ) is an enzyme involved in processing of polyprotein which is translated from viral RNA. Inhibition of this protease will block the replication of the virus and thus is an important drug target. Michael acceptors can act as cysteine protease inhibitors, one such inhibitor is N3. It can reversibly bind to M pro which then blocks its activity by forming a covalent bond with catalytic cysteine after the nucleophilic attack (Jin et al., 2020; Santos & Moreira, 2007) . The crystal structure of the M pro of SARS-CoV-2 with N3 inhibitor has been recently reported, and this can be taken as a control for discovering new inhibitors. Alpha-ketoamide based inhibitors have also been reported; one of the inhibitors has shown low micromolar EC-50 against SARS-CoV-2 .

M pro is a homodimer, each monomer consisting of three domains. Domain 1 consists of residues 10-99, domain 2 consists of residues 100-182 and residues 198-303 form domain 3 of Mpro. Domain 3 is responsible for regulating the dimerization of M pro . Catalytic dyad of protein is formed by residues His 41 and Cys145. Dimerization of enzyme is necessary for catalytic activity since it helps in making of S1 pocket of the substrate binding site (Anand et al., 2003; Jin et al., 2020) . Thus, any drug-like candidate which strongly binds to S1 site or inhibits the dimerization process can potentially inhibit the replication of virus. Docking and molecular dynamics (MD) simulation have emerged as a tool to predict the putative drugs if the target protein structure is available.

Recently, several research groups have reported some inhibitors of SARS-CoV-2 main protease (Adem et al., 2020; Khan et al., 2020; Ton et al., 2020; Verma et al., 2020; Zhang et al., 2020) . Antiviral drugs and natural compounds are some of the widely explored class of compounds due to their good binding interaction with the main protease. In our study, we have carried out in-silico screening of a range of FDA-approved antiviral, antimalarial drugs, some Ayurveda medicines and some natural polyphenols targeting M pro . We have arranged the obtained hits according to their interaction energies and top compounds have been subjected to MD simulations in much more realistic environment. MM-GBSA methodology was used to obtain more accurate interaction energies and they are compared with the interaction energy of N3 with M pro .

The crystal structure of the free enzyme of the SARS-CoV-2 main protease (PDB: 6Y2E) was recently published by Zhang et al. (2020) . Its substrate-binding pocket was chosen for the screening of compounds as obtained from M pro -N3 complex ( Figure S1 ). The ligand database was prepared by retrieving the structures of FDA approved antiviral and antimalarial drugs from Drugbank (Wishart et al., 2006) , structures of Ayurveda compounds from PubChem (Kim et al., 2019) and structures of polyphenols were drawn using Marvin Sketch (MarvinSketch 17.23.0, ChemAxon). Structures of EGCG scaffold were obtained from the Zinc database (Sterling & Irwin, 2015) .

AutoDock Vina (Trott & Olson, 2010) was used for the screening of ligand database. AUTODOCK 4 (Morris et al., 2009) was used to prepare the ligand structure for docking. Docking generates several poses of ligand inside the binding pocket, the poses showing minimum binding energy were chosen for carrying out further studies. OpenBabel (O'Boyle et al., 2011; Open Babel-4.2 .1) was used for obtaining PDB structures of ligands from PDBQT and for adding the protons. Various interactions like hydrophobic and hydrogen bonding interactions between ligand and protein were visualized using LigPlot (Laskowski & Swindells, 2011) .

MD simulations were carried out on Amber18 package (Case et al., 2018) . Ligand parameters were obtained from general Amber force field (GAFF2) (Tr€ ag & Zahn, 2019) and AM1 BCC method was used to derive the charges. Bonded and nonbonded parameters for protein were obtained from the Amber 14SB force field. Docked protein-ligand complexes were solvated in a 10 nm truncated octahedron with TIP3P water molecules (Jorgensen et al., 1983) and counter ions were added to neutralize the system. The study utilized periodic boundary conditions and PME summation (Petersen, 1995) for electrostatic calculations.

The shake methodology was applied to restrict covalently bonded hydrogen atoms. Constant pressure condition was maintained using Berendsen thermostat (Berendsen et al., 1984) . Time step of 2 femtosecond with 9 Å cut off for nonbonded interactions were applied. Protein-ligand complexes were energy minimized in two steps, first using 250 steps of steepest descent followed by 750 steps of conjugate gradient method. Equilibration was also carried out in two steps, heating the systems at 300 K followed by simulation of complexes by decreasing the force slowly up to 0.1 N. Next, fully unrestricted equilibration was performed for 5 ns. The convergence of various system properties was monitored. The production run was performed for 1500 ns under NPT ensemble. Simulation of protein without any ligand was also carried out. For M pro -N3 complex, available crystal structure (PDB: 6LU7 (Jin et al., 2020) ) was used and simulation was carried out as mentioned above. 500 ns simulations of protein were also performed with compounds having scaffold of EGCG.

For analysis, Amber trajectory was converted to Gromacs (Abraham et al., 2015) trajectory using python script. For checking the stability of protein due to ligand binding, root mean square deviation (RMSD) was monitored with respect to the reference structure (first frame) for C a atoms of protein. In order to see the residue level fluctuations, root mean Scheme 1. Thermodynamic cycle utilized for MM-GBSA calculation.

square fluctuation (RMSF) was observed for last 300 ns for C a atoms of protein. For obtaining distance distribution, distances between center of mass of active site residues and center of mass of ligands were calculated for last 300 ns and distribution was obtained from the histogram analysis tool of MS-Excel. Clustering analysis was done by taking the last 300 ns trajectory, using the single linkage method. In this, a cluster was formed by subsequent addition of structures whose distance is less than 0.1 nm to any element of the cluster, if the distance is more than 0.1 nm a new cluster was formed.

MM-GBSA method was employed for calculating the free energy difference between bound and unbound form of receptor and for this MMPBSA.py tool of Amber18 was utilized. MMPBSA.py is a post-processing tool which extracts snapshots of complex, protein and ligand from the same trajectory of solvated complex. Free energy was calculated according to the following thermodynamic cycle (Scheme 1):

free energies have contributions from electrostatic and non-electrostatic interactions; electrostatic contribution was obtained by solving the Generalized Born (GB) equation. Here, a modified GB model (Onufriev & Case, 2019) was used for electrostatic part calculations. Non-electrostatic part was considered to be proportional to the total solvent accessible area of the molecule and was obtained from the linear combination of pairwise overlaps (LCPO) algorithm (Weiser et al., 1999) . Free energy change in vacuum was obtained by taking average interaction energy of protein and ligand from molecular mechanics and considering entropy change upon binding. For the comparison of the binding energies of various ligands to the same receptor, entropy contributions were not taken into account.

In-silico screening of antiviral, antimalarial drugs, polyphenols and ayurvedic compounds through molecular docking with M pro In order to find the potential binder to the substrate site of M pro (PDB: 6Y2E ), a total of 125 FDA approved drugs and compounds were screened utilizing molecular docking studies. Out of the total, 31 compounds have binding energy below À6 kcal/mol, 52 compounds have binding energy between À6 and À7 kcal/mol, 35 compounds have binding energy between À7 and À8 kcal/mol and only 7 compounds have binding energy above and equal to À8 kcal/ mol (Table S1 ). Compounds having binding energies above or equal to À8 kcal/mol were selected for carrying out MD simulation to understand their molecular level interactions with the receptor, their binding energy and interacting residues are listed in Table 1 and their structures are presented in Figure S2 . The selected seven compounds were Epigallocatechin gallate (EGCG), Delavirdine, Dolutegravir, Indinavir, Artesunate, Tinosporin B and Withaferin A. Their interactions with the receptor are shown in Figure S4 . Epigallocatechin gallate (EGCG) is a polyphenolic compound found in green tea and has been shown to have antiviral activity. The calculated binding energy between EGCG and Mpro from docking is À8.3 kcal/ mol and EGCG.

Delavirdine, Dolutegravir and Indinavir are FDA approved antiviral drugs used for the treatment of Human Immunodeficiency virus (HIV). Binding energies obtained for delavirdine, dolutegravir and indinavir are À8.1 kcal/mol, À8.6 kcal/mol and À8.0 kcal/mol, respectively.

Artesunate is one of the most rapid-acting antimalarial drugs and it is a semi-synthetic derivative of artemisinin. The calculated binding energy for protein-artesunate complex is À8 kcal/mol. Two Ayurveda compounds also showed significant binding to the target, one is tinosporin B which is a diterpenoid furanolactones extracted from plant tinospora cardyfolia. Tinosporin has anti-inflammatory, anti-microbial, antihypertensive and antiviral properties. Another Ayurveda compound which qualified our binding energy criterion is Withaferin A, it is extracted from the leaves of the Indian plant Withania somnifera (ashwagandha) and exhibits chemo preventive, anti-cancer and immunomodulatory actions. Calculated binding energies for tinosporin A and withaferin A were found to be equal to À8.0 kcal/mol and À8.9 kcal/ mol, respectively.

MD simulations were performed to ascertain the stability of docked complexes. RMSD values of C a were plotted with respect to the first frame for all the complexes (Figure 1(a) ). For a better comparison, the average values of RMSD for last 300 ns were plotted along with standard deviation (Figure  1(b) ). For protein with N3 inhibitor, the RMSD value was observed to be equal to 0.34 nm (±0.04). The RMSD value for the Artesunate complex increased from 0.25 nm (±0.01) for protein without ligand to 0.59 nm (±0.02), which indicated , 41, [44] [45] [46] 49, 142, 145, [164] [165] [166] 189 2 EGCG À8.3 25, 41, 46, 49, 140, 141, 144, 142, 145, 165, 166, 189 3 Withaferin À8.9 24, 25, 41, [44] [45] [46] 49, [140] [141] [142] 164, 166 4 Delavirdine À8.1 [25] [26] [27] 41, 46, 49, [140] [141] [142] [143] 145, 163, 166 5 Dolutegravir À8.6 24, 25, 41, 45, 46, 142, 143, 145, 166 6 Artesunate À8.0 [24] [25] [26] [27] 41, 46, 49, [140] [141] [142] [143] [144] [145] 163, 165, 166 7 Indinavir À8.0 25, 26, 41, 49, [140] [141] [142] 145, 163, 164, 166, 189 increase in structural fluctuations due to ligand binding. After 1100 ns, C a RMSD values for all the complexes were not changing much, signifying a stable complexation between protein and ligand. Next, residue level fluctuations were seen through root mean square fluctuation (RMSF) analysis (Figure 2 ). In N3complex, for all the residues, except for terminal residues, RMSF values were not changing much and values observed below 0.3 nm (Figure 2(a) ). Increased fluctuations were observed for the residues Gln 189, Thr 190, Ala 191, Gln 192, Ala 193 and 194 as compared to N3 bound protein. This trend was observed for all the complexes. For EGCG, withaferin A, dolutegravir and artesunate complexes ( Figure  2(c-e,h) ), RMSF values were found to be similar to N3 bound protein. For tinosporin B, delavirdine and indinavir, larger fluctuations were also observed for the residues 44-60, which includes some ligand interacting residues Cys 44, Thr 45, Ser 45 and Met 49 (Figure 2(b,f,g) ). Our RMSF analysis suggests that upon binding of tinosporin B, delavirdine or indinavir, fluctuation is more in a small region of protein and EGCG, withaferin A, dolutegravir and artesunate complexes remain stable.

Furthermore, to ensure the stable binding of ligand inside the binding pocket during simulation, distances between center of mass of ligand and center of mass of active site residues His 41,Cys 145,Glu 166 and Gln 189 were calculated for all the complexes for last 300 ns and frequency distributions were plotted (Figure 3) . Distribution was centered within 1 nm for N3, EGCG, Withaferin A, Dolutegravir and Artesunate for all the four residues, whereas, broad distance distributions were observed for Tinosporin B, Delavirdine and Indinavir complexes above 2 nm. A broad distribution at higher distance values can be due to weak protein-ligand complexation at the active site. Therefore, only EGCG, withaferin A, dolutegravir and artesunate show tight binding to the active site based on the distance distribution analysis.

Subsequently, clustering analysis was done on the last 300 ns trajectory and a representative structure was obtained which then visualized through LigPlot to see the change in molecular level interaction during simulations ( Figure S3 ).

The obtained representative structures from clustering analysis were compared with the docked structures before the start of simulation, for the active site interactions ( Figure  S3 ). For Delavirdine and indinavir, no active site interactions were seen and binding site for these ligands were changed completely. Tinosporin B with one intact contact also showed weak binding interactions. For protein-EGCG complex, number of active site interactions increased to six s, indicating a good binding of ligand to the receptor. Withaferin A and dolutegravir showed four and two active site interactions, respectively, and also seen to be well within their desired binding pockets. Artesunate exhibited five active site interactions. Therefore, tinosporin B, indinavir and delavirdine have been ruled out to be tested as a drug candidate since these were not stable inside the binding pocket. EGCG, withaferin A, dolutegravir, artesunate and their analogs can be considered as good antidotes for COVID-19 and further studies can be carried out on them.

The binding of EGCG to the active site of M pro is found to be efficient; therefore, all the compounds having scaffold of EGCG were also screened through molecular docking and MD simulations. A total of 132 compounds were docked to M pro and three compounds (Figure 4) showing highest binding energies were subjected to 500 ns MD simulation. Their binding energies are given in Table 2 . RMSD and clustering analyses were performed (Figures S4 and S5 ). Stable C a atoms RMSD and conserved binding pocket during MM-GBSA approach for calculating binding free energy of complex MM-GBSA approach utilizes molecular mechanics, the generalized Born (GB) model and solvent accessibility method for free energy calculations. Binding free energies for all the complexes including Mpro-EGCG analogs were calculated using MM-GBSA approach (Table 2) . For N3, tinosporin B, EGCG, withaferin A, delavirdine, dolutegravir, indinavir and artesunate complexes, last 300 ns trajectory from 1500 ns MD trajectory was taken and for complexes of EGCG analogs, last 100 ns trajectory from 500 ns was selected for this calculation. For N3-M pro complex, binding energy was found to be equal to À28.79 (±3.73) kcal/mol. Among all the complexes, withaferin A, EGCG, dolutegravir, artesunate, ZINC21992196 and ZINC169337541 showed significant binding energy when compared with M pro -N3 complex. Tinosporin B, delavirdine, indinavir and ZINC3870415 showed low binding energies. The similarity ensemble approach (SEA) predicted the probable targets for ZINC21992196 and ZINC 169337541, which indicates that these compounds may act as protease inhibitors (Keiser et al., 2007) . Our MM-GBSA results support our previous findings and predict that EGCG, withaferin A, dolutegravir and artesunate may act as potential inhibitor of SARS-CoV-2 M pro . Favorable interaction of M pro with EGCG analogs also propose that compounds or drugs having same scaffold can also be tested for their inhibitory actions.

Our docking and MD studies suggest EGCG, withaferin A, doutegravir, artesunate and their analogs may act as an inhibitor for the main protease of SARS-CoV-2. EGCG which is a major component of green tea is capable of showing antiviral activity against many DNA and RNA viruses, like adenovirus, influenza virus, human immunodeficiency virus (HIV) and coronavirus, by inhibiting various stages of viral infection (Benelli et al., 2002; Ho et al., 2009; Nance et al., 2009; Song et al., 2005; Weber et al., 2003) . Similarly, withaferin A which is a component of ayurvedic plant Withania somnifera (ashwagandha) also exhibits antiviral properties against influenza virus (Cai et al., 2015) . Artesunate, a semisynthetic derivative of artemisinin, is a well-known malaria drug and has the potential to fight against many viruses (Efferth et al., 2008; Lisewski et al., 2014) . Dolutegravir is an antiretroviral drug used along with other medications to treat HIV/AIDS (Min et al., 2010) . Supported by previous literature and our results we propose EGCG, withaferin A, dolutegravir and artesunate as potential drugs for COVID-19 and the compounds having similar scaffolds can also be tested for their potency. Furthermore, experimental work needs to be done to verify their use as a drug.

GROMACS user manual

Identification of potent COVID-19 main protease (Mpro) inhibitors from natural polyphenols: an in silico strategy unveils a hope against CORONA

Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs

Anti-invasive effects of green tea polyphenol epigallocatechin-3-gallate (EGCG), a natural inhibitor of metallo and serine proteases

Molecular dynamics with coupling to an external bath

Promising anti-influenza properties of active constituent of Withania somnifera ayurvedic herb in targeting neuraminidase of H1N1 influenza: Computational study

The antiviral activities of artemisinin and artesunate. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2

Antiviral effect of epigallocatechin gallate on enterovirus 71

Structure of M(pro) from COVID-19 virus and discovery of its inhibitors

Comparison of simple potential functions for simulating liquid water

Relating protein pharmacology by ligand chemistry

Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach

LigPlotþ: Multiple ligand-protein interaction diagrams for drug discovery

Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate

Marvin was used for drawing the chemical structures

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

Preclinical development of the green tea catechin, epigallocatechin gallate, as an HIV-1 therapy

Open Babel: An open chemical toolbox

Generalized born implicit solvent models for biomolecules

Accuracy and efficiency of the particle mesh Ewald method

Chloroquine or hydroxychloroquine for prophylaxis of COVID-19

Michael acceptors as cysteine protease inhibitors

COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries

Antiviral effect of catechins in green tea on influenza virus

ZINC 15-ligand discovery for everyone

Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 1.3 billion compounds

Improved GAFF2 parameters for fluorinated alkanes and mixed hydro-and fluorocarbons

AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

Potential inhibitors of SARS-CoV-2 main protease (Mpro) identified from the library of FDA approved drugs using molecular docking studies

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Inhibition of adenovirus infection and adenain by green tea catechins

Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO)

Drugbank: A comprehensive resource for in silico drug discovery and exploration

A new coronavirus associated with human respiratory disease in China

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors

A pneumonia outbreak associated with a new coronavirus of probable bat origin

We acknowledge Supercomputing Facility for Bioinformatics and Computational Biology (SCFBio), IIT Delhi, for granting the access of AMBER. We thank IIT Delhi HPC facility for computational resources.

SS performed research, analyzed data and wrote the initial draft. SD designed research, provided the facility and edited the paper for final version.

No potential conflict of interest was reported by the authors.

SS thank University Grants Commission (UGC) for financial support.